JP2005527523A - ＡｎｇＩＩ介在性疾病を処置するための４−（４−メチルピペラジン−１−イルメチル）−Ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イル−アミノ］フェニル］−ベンズアミド - Google Patents

ＡｎｇＩＩ介在性疾病を処置するための４−（４−メチルピペラジン−１−イルメチル）−Ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イル−アミノ］フェニル］−ベンズアミド Download PDF

Info

Publication number
JP2005527523A
JP2005527523A JP2003575945A JP2003575945A JP2005527523A JP 2005527523 A JP2005527523 A JP 2005527523A JP 2003575945 A JP2003575945 A JP 2003575945A JP 2003575945 A JP2003575945 A JP 2003575945A JP 2005527523 A JP2005527523 A JP 2005527523A
Authority
JP
Japan
Prior art keywords
angiotensin
methyl
hypertension
hypertrophy
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003575945A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005527523A5 (enExample
Inventor
リチャード・アーネスト・ギルバート
ダーレン・ジェイムズ・ケリー
デイビッド・ルイス・フェルドマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Melbourne
Original Assignee
University of Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0206216A external-priority patent/GB0206216D0/en
Priority claimed from GB0206217A external-priority patent/GB0206217D0/en
Priority claimed from GB0217505A external-priority patent/GB0217505D0/en
Application filed by University of Melbourne filed Critical University of Melbourne
Publication of JP2005527523A publication Critical patent/JP2005527523A/ja
Publication of JP2005527523A5 publication Critical patent/JP2005527523A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2003575945A 2002-03-15 2003-03-14 ＡｎｇＩＩ介在性疾病を処置するための４−（４−メチルピペラジン−１−イルメチル）−Ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イル−アミノ］フェニル］−ベンズアミド Pending JP2005527523A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0206216A GB0206216D0 (en) 2002-03-15 2002-03-15 Organic compounds
GB0206217A GB0206217D0 (en) 2002-03-15 2002-03-15 Organic compounds
GB0217505A GB0217505D0 (en) 2002-07-29 2002-07-29 Organic compounds
PCT/EP2003/002709 WO2003077892A2 (en) 2002-03-15 2003-03-14 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide for treating ang ii-mediated diseases

Publications (2)

Publication Number Publication Date
JP2005527523A true JP2005527523A (ja) 2005-09-15
JP2005527523A5 JP2005527523A5 (enExample) 2006-08-03

Family

ID=28045959

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003575945A Pending JP2005527523A (ja) 2002-03-15 2003-03-14 ＡｎｇＩＩ介在性疾病を処置するための４−（４−メチルピペラジン−１−イルメチル）−Ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イル−アミノ］フェニル］−ベンズアミド

Country Status (11)

Country Link
US (1) US20050124624A1 (enExample)
EP (1) EP1487424B1 (enExample)
JP (1) JP2005527523A (enExample)
AT (1) ATE339197T1 (enExample)
AU (1) AU2003233946A1 (enExample)
CY (1) CY1105839T1 (enExample)
DE (1) DE60308337T2 (enExample)
DK (1) DK1487424T3 (enExample)
ES (1) ES2274234T3 (enExample)
PT (1) PT1487424E (enExample)
WO (1) WO2003077892A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006505582A (ja) * 2002-10-25 2006-02-16 ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド 肺高血圧症の処置を目的としたｎ−｛５−［４−（４−メチルピペラジノメチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリジン−アミンの使用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750160B2 (en) 2003-11-13 2010-07-06 Ambit Biosciences Corporation Isoxazolyl urea derivatives as kinase modulators
WO2005070406A1 (en) * 2004-01-22 2005-08-04 Novartis Ag Combination of organic compounds
GB0401761D0 (en) * 2004-01-27 2004-03-03 Novartis Ag Organic compounds
MY144177A (en) * 2004-02-04 2011-08-15 Novartis Ag Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide.
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
EP1741432A1 (de) * 2005-07-07 2007-01-10 Universitätsklinikum Freiburg Tyrosinkinase-Inhibitor Imatinib zur Behandlung von Bluthochdruck
DE102005042544A1 (de) * 2005-09-07 2007-03-08 Ernst-Moritz-Arndt-Universität Beeinflussung des kardialen Fc-Rezeptors zur Behandlung der dilatativen Kardiomyopathie
WO2007084949A2 (en) * 2006-01-18 2007-07-26 The Uab Research Foundation Modulators of cardiac cell hypertrophy and hyperplasia
KR20080104149A (ko) * 2006-03-13 2008-12-01 엔싸이시브 파마슈티칼즈 인코퍼레이티드 확장기 심장 부전의 치료를 위한 방법 및 조성물
WO2007106467A2 (en) * 2006-03-13 2007-09-20 Encysive Pharmaceuticals, Inc. Polymorphs of n-(4-chloro-3-methyl-5-isoxazolyl)2-[2-methyl-4,5-(methylenedioxy) phenylacetyl]thiophene-3-sulfonamide, sodium salt
MX2009002336A (es) * 2006-09-01 2009-03-20 Teva Pharma Composiciones de imatinib.
TW201006823A (en) * 2008-07-14 2010-02-16 Novartis Ag Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
US20220229072A1 (en) 2019-06-04 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2025024488A2 (en) * 2023-07-27 2025-01-30 Mineralys Therapeutics, Inc. Methods of treating hypertension with a combination of lorundrostat and two or more anti-hypertensive medications

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001510192A (ja) * 1997-07-18 2001-07-31 ノバルティス アクチエンゲゼルシャフト Ｎ−フェニル−２−ピリミジンアミン誘導体の結晶変形、その製造法およびその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US20010051631A1 (en) * 1994-07-15 2001-12-13 Muneo Takatani Tricyclic compounds, their production and use
ATE209047T1 (de) * 1995-06-07 2001-12-15 Searle & Co Epoxysteroide aldosteronantagonist und angiotensin ii rezeptor antagonist kombinationstherapie zur behandlung von congestivem herzversagen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001510192A (ja) * 1997-07-18 2001-07-31 ノバルティス アクチエンゲゼルシャフト Ｎ−フェニル−２−ピリミジンアミン誘導体の結晶変形、その製造法およびその使用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006505582A (ja) * 2002-10-25 2006-02-16 ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド 肺高血圧症の処置を目的としたｎ−｛５−［４−（４−メチルピペラジノメチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリジン−アミンの使用
JP4942297B2 (ja) * 2002-10-25 2012-05-30 ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド 肺高血圧症の処置を目的としたｎ−｛５−［４−（４−メチルピペラジノメチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリジン−アミンの使用

Also Published As

Publication number Publication date
WO2003077892A2 (en) 2003-09-25
ES2274234T3 (es) 2007-05-16
WO2003077892A3 (en) 2003-12-24
PT1487424E (pt) 2007-01-31
DE60308337D1 (de) 2006-10-26
ATE339197T1 (de) 2006-10-15
DE60308337T2 (de) 2007-09-20
AU2003233946A8 (en) 2003-09-29
US20050124624A1 (en) 2005-06-09
EP1487424A2 (en) 2004-12-22
DK1487424T3 (da) 2007-01-08
AU2003233946A1 (en) 2003-09-29
CY1105839T1 (el) 2011-04-06
EP1487424B1 (en) 2006-09-13

Similar Documents

Publication Publication Date Title
JP2005527523A (ja) ＡｎｇＩＩ介在性疾病を処置するための４−（４−メチルピペラジン−１−イルメチル）−Ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イル−アミノ］フェニル］−ベンズアミド
JP2008515905A (ja) 有機化合物の組合せ剤
US20030139429A1 (en) Combinations
CA2495350C (en) Use of lck inhibitor for treatment of immunologic diseases
WO2007106708A2 (en) Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
JP2005502643A (ja) 白血病処置のための単独またはｓｔｉ５７１と組み合せたｃ−ｓｒｃインヒビターの使用
JP2005504113A (ja) Ｐｄｅ−ｖ阻害剤および他薬剤の医薬組合わせ
EP1789051A1 (en) Endothelin a receptor (eta) antagonists in combination with phosphodiesterase 5 inhibitors (pde5) and uses thereof
KR20070102544A (ko) 유기 화합물의 조합물
DK3027183T3 (en) SELECTIVE AT2 RECEPTOR AGONISTS FOR USING CACKSY TREATMENT
JP2005527523A5 (enExample)
JP4499359B2 (ja) シグナル変換阻害剤とエポチロン誘導体とを含有してなる組合せ剤
US20110124670A1 (en) Use of Pyrimidylaminobenzamide Derivatives for the Treatment of Fibrosis
KR20080066776A (ko) 안지오텐신 ⅱ 수용체 봉쇄제, 칼슘 채널 봉쇄제 및 다른활성 약제의 조합물
HK1247119A1 (zh) 一种治疗方法和用於所述治疗方法中的化合物
AU2006230674A8 (en) Methods for the Treatment of Synucleinopathies
US20080234285A1 (en) Combination of Organic Compounds
CN108778334A (zh) 用于治疗肾脏疾病的药物
KR20080044277A (ko) 유기 화합물의 조합물
Dzielak Comparative pharmacology of the angiotensin II receptor antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100708

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100802

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20101210